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Toxicity of lipopolysaccharide (LPS) (endotoxin) is, to a large extent, mediated by the activation of
monocytes/macrophages and subsequent release of monokines, such as interleukin-I (IL-1) and tumor necrosis
factor alpha (TNF-a). It is known that LPS binds readily to serum lipoproteins and that LPS-lipoprotein
complexes are less toxic than unbound LPS. Here we present data analyzing the impact of the LPS-serum
interaction at the cellular level. By measuring IL-1 TNF-a, and IL-6, the interaction of different LPSs or lipid
A with human serum could be shown to prevent the activation of human monocytes. The amounts of LPS
inactivated by normal human serum did not exceed 10 ng/ml. The LPS-inactivating capacity of serum was
shown to be a function of the lipoproteins. Other serum components, such as naturally occurring anti-LPS
immunoglobulin G, complement, or nutritive lipids, had no significant influence in our system. Our
experiments suggest that serum lipoproteins control endotoxin-induced monocyte activation and monokine
release.
Endotoxin (lipopolysaccharide [LPS]) is the main patho-
genic factor of gram-negative bacteria. The most prominent
toxic effects of LPS in vivo are fever, diarrhea, and hypo-
tension, which may lead to shock and death. Minimal toxic
concentrations of LPS vary widely in mammalian species,
with humans being one of the most sensitive. Serum is
known to interact with LPS and decrease its toxicity, a fact
which has been under investigation since LPS was first
isolated more than 30 years ago. In early experiments (31),
inhibition of pyrogenicity was seen after incubation of bac-
terial polysaccharide with native serum as well as with
serum treated at 58°C. One hypothesis was that detoxifica-
tion of LPS by proteins was due to enzymatic degradation of
LPS (34, 45). This was not, however, supported by other
experiments indicating protein-endotoxin complexes, possi-
bly involving immunoglobulins (32). Later (41), it was found
that LPS detoxification occurred in many different mamma-
lian species, that it was independent of the hemolytic com-
plement system, and that it was optimal at 37°C. Although
partial deacylation of LPS may occur inside neutrophils (23),
it seems that LPS molecules, which remain in plasma, do not
undergo major cleavage for many hours (20). It is firmly
established that LPS binds to plasma lipoproteins (8, 39).
The evidence for this was first reported by Skarnes in 1968
(33). LPS binding to lipoproteins, more specifically to the
high-density lipoproteins (HDL), has been shown to dimin-
ish the LPS toxicity in vivo (20, 24, 38) with respect to
pyrogenicity, neutropenia, and anticomplementary activity.
Inactivation of LPS by HDL did not, however, proceed to
completion, and HDL-complexed LPS retained much of its
ability to induce hypotension, disseminated intravascular
coagulation, and death.
The actual mechanisms of LPS toxicity are not fully
understood. Nevertheless, there is accumulating evidence
suggesting that LPS toxicity is mediated by cytokines,
namely, tumor necrosis factor alpha-cachectin (TNF-ca),
interleukin-1 (IL-1), and IL-6. In vitro, these monokines are
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concomitantly produced by cells of the monocyte/macro-
phage lineage, fibroblasts, or endothelial cells upon stimula-
tion by minute amounts of LPS. The central role of mono-
cytes/macrophages in mediating LPS toxicity in vivo has
been emphasized by several observations, including adop-
tive transfer of LPS sensitivity by C3H/HeN macrophages
into LPS-nonsensitive C3H/HeJ mice (9). Further, TNF or
IL-1 could mimic the whole spectrum of LPS toxicity in
animals (18, 19, 30, 36), and passive immunization against
TNF could prevent some of the LPS toxicity in vivo (4, 21,
37). IL-6 (previously hepatocyte-stimulating factor) is
known to be the principal inducer of the acute-phase re-
sponse of the liver (12, 13).
Inhibition of LPS effects by serum components has been
demonstrated by several authors (15, 29, 42, 43), using the
Limulus amebocyte lysate assay. Recently, we have shown
that under certain conditions, interaction of serum with LPS
could prevent LPS-induced mediator release (27, 28). Pre-
liminary results in our laboratory indicated that those serum
components which can inhibit LPS recognition by the Lim-
ulus amebocyte lysate assay may not be identical with the
effective inhibitors of LPS-induced mediator release by
human monocytes. It is the prime aim of this study to
establish the extent to which serum interferes with LPS-
induced monokine release, what the kinetics of this effect
are, and which serum components are involved. In most
experiments, IL-1 was measured and taken as repre-
sentative, while in some experiments, TNFa and IL-6 re-
lease were also measured.
(This work was partially presented ;n abstract form at the
XIX. Tagung der Deutschen Gesellschaft fur Immunologie,
Ulm, Federal Republic of Germany, October 1987, and at
the 1st International Congress on the Immune Consequences
of Trauma, Shock and Sepsis, Munich, Federal Republic of
Germany, March 1988.)
MATERIALS AND METHODS
Materials. LPSs derived from Escherichia coli 0128:B12,
0127:B8, O111:B4, 055:B5, 026:B6, Salmonella minnesota
2237
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Re595 and Salmonella abortus equi were purchased from
Sigma Chemical Co. (St. Louis, Mo.). LPS Salmonella typhi
(strain 0901, no. 3124-25-6) was from Difco Laboratories
(Detroit, Mich.). LPS S. minnesota was extracted by a
phenol-chloroform-petroleum-ether extraction procedure;
all other LPSs were phenol-extracted preparations and con-
tained the complete molecule, including the 0 antigen. LPS
was reconstituted in pyrogen-free distilled water at 1 mg/ml,
sonicated for 10 min, passed through a 0.22-,um-pore-size
filter (no. 8110; Costar, Fernwald, Federal Republic of
Germany), and stored as stock solution at 4°C for a maxi-
mum of 4 months. Synthetic lipid A LA-15-PP(506) was
obtained from Daiichi Co. (Tokyo, Japan), reconstituted as
recommended by the producer, stored at 4°C as stock
solution, and used within 2 weeks. Culture medium was
RPMI 1640 (GIBCO, Karlsruhe, Federal Republic of Ger-
many) containing 25 U of penicillin-streptomycin per ml, 2.5
mM N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid
(HEPES) buffer, 0.02 mM 2-mercaptoethanol, and 6 mM
L-glutamine and adjusted to pH 7.2 with 1 N HCI. Pyrogen-
free water was prepared by bidistillation and frequently
tested with a Limulus assay (Pyroquant, Walldorf, Federal
Republic of Germany). All laboratory techniques were per-
formed with disposable plastic materials to ensure pyrogen-
free conditions throughout. C3H/HeJ-mice (4 to 7 weeks old)
and Lewis rats (20 weeks old) were obtained from Bomholt-
gard (Ry, Denmark).
Preparation of sera. To obtain human serum, blood was
drawn from healthy donors (blood group AB or A, checked
for absence of irregular antibodies against erythrocytes),
collected in bottles, and allowed to clot at 4°C overnight. The
serum was withdrawn and frozen at -20°C until tested or
immediately used for further preparation. Thawing was
performed in a 37°C water bath. Serum fractions separated
by ultracentrifugation were tested immediately after prepa-
ration. Samples of serum fractions stored at -20°C could
also be used and produced equivalent results. Rat serum was
obtained from Lewis rats by puncture of the abdominal
artery under ether anesthesia and immediately used in ex-
periments. Fetal calf sera (FCS) were purchased from dif-
ferent suppliers and pretested on more than 10 human
monocyte preparations for lack of direct IL-1-inducing ac-
tivity (28). Only those sera which were negative with all
human monocytes were used in our experiments. One of
them (lot no. 3R07; Seramed, West Berlin, Federal Republic
of Germany) was used throughout the monocyte prepara-
tion. All sera were filtered through 0.45-p.m-pore-size dis-
posable filterware (Nalge Co., Rochester, N.Y.).
Preparation of serum fractions. (i) Density gradient ultra-
centrifugation. Human serum was adjusted with KBr to a
density of 1.21 g/cm3 and ultracentifuged in a SW50 Ti rotor
(Beckman, Munich, Federal Republic of Germany) at
226,000 x g for 40 h at 4°C. The top one-quarter was
separated from the lower three-quarters ("1.21 bottom") of
the tubes (Quick-Seal; Beckman) by using needles for per-
forating the plastic. Representative samples were controlled
for density. The lipoprotein-free serum ("1.21 bottom") was
tested for apolipoproteins Al, All, and B; cholesterol; and
phospholipids by routine techniques and found to contain
less than 3% of the physiological serum concentrations. Both
serum fractions were dialyzed extensively under sterile
conditions against RPMI 1640. Lipoprotein-free serum was
diluted with RPMI 1640 to the original volume before use in
monokine production. The upper fraction, which contained
virtually all lipoproteins, was checked for apolipoproteins
Al, AII, and B.
(ii) Kaolin absorption. Kaolin (E. Merck AG, Darmstadt,
Federal Republic of Germany) was baked 4 h at 250°C and
thoroughly washed. Human serum (10 ml) was treated with
5 g of kaolin gently held in suspension for 1.5 h at 4°C.
Kaolin was removed from the suspension by centrifugation
at 2,000 x g for 1 h and subsequent 0.2-p.m-pore-size
filtration.
(iii) Solvent extraction. Lipoprotein-free serum was also
prepared by using a solvent system as described previously
(7). Kaolin-absorbed or solvent-treated sera proved to be
depleted of all lipoproteins, as controlled by apolipoprotein
content.
Preparation of monocytes and monokine production. Mono-
nuclear cells prepared by Ficoll density gradient centrifuga-
tion of buffy coat layers from normal blood units (ACD
stabilizer, blood group 0 or A) were incubated for 2 h at 37°C
in four (10 ml each) plastic flasks (no. 3024; Falcon, Heidel-
berg, Federal Republic of Germany) in RPMI 1640 medium
containing 5% FCS. Nonadherent cells were removed by
washing three times with RPMI 1640-FCS at 37°C. Adherent
cells were recovered by gentle washing after 1 h of incuba-
tion on ice, adjusted to 106 cells per ml in RPMI 1640-FCS,
and immediately used in monokine production. More than
90% of the cells were verified as monocytes by nonspecific
esterase staining and immunofluorescence with monoclonal
antibodies.
For testing the LPS-serum interaction, RPMI 1640 con-
taining either 20% serum, lipoprotein-free serum, or lipopro-
tein-reconstituted serum was incubated with LPS for 24 h at
37°C (total volume of 100 [LI; no. 3595; Costar) before the
addition of monocytes. Alternatively, RPMI 1640 containing
20% serum was incubated without LPS and LPS was added
immediately after the start of the culture. As a further
control, LPS was incubated with RPMI 1640 alone and
serum was reconstituted at start of culture. Cultures were
initiated with 100 [L1 of monocyte suspension added to
microdilution wells containing 100 p.l of the serum-supple-
mented RPMI 1640. In another control, all media and agents
(RPMI 1640, serum, LPS, and monocytes) were added at
once without any incubation prior to culture. Serum or
lipoprotein-free serum was always present at a final concen-
tration of 10%. In reconstitution experiments, the lipopro-
tein-rich fraction was added to the lipoprotein-free serum to
yield concentrations as indicated in the results. The culture
supernatants were harvested after 24 h of monocyte culture
and stored at -20°C until being tested for monokines.
IL-1 assay. IL-1 was determined in the costimulator assay
as described previously (26). In brief, supernatants were
titrated and C3H/HeJ mouse thymocytes were added at 7.5
x 106 cells per ml and incubated for 72 h at 37°C in the
presence of suboptimal phytohemagglutinin concentrations
(50 pg/ml; no. 27658; Serva, Heidelberg). Cultures were
pulsed with [3H]thymidine for the final 24 h. Background
levels in the presence of LPS and suboptimal phytohemag-
glutinin were always less than 800 ± 200 cpm (mean ±
standard deviation; done in triplicate). The minimal potenti-
ation accepted as significant was a 2.5-fold increase in
incorporated radioactivity over background. International
units of IL-1 were calculated by comparison to the interna-
tional standard for IL-1 (NBSB, Oxford, England) by using
a computer-based program (Hochgeladen, Neu-Ulm, Fed-
eral Republic of Germany) for logit transformation.
TNF-o assay. TNF-cx was determined by enzyme-linked
immunosorbent assay (ELISA) by using a polyclonal rabbit
antiserum as described previously (17).
IL-6 assay. IL-6 was determined by using the IL-6-de-
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pendent cell line 7TD1 (kindly provided by J. van Snick,
Brussels, Belgium). Supernatants of monocyte cultures were
titrated, and 7TD1 cells were added at 2.5 x 104 cells per ml
in 1% FCS and incubated for 72 h at 37°C. Cultures were
pulsed with [3H]thymidine for the final 24 h. Units were
calculated by comparison to an arbitrary standard for IL-6.
Assay for naturally occurring anti-LPS antibodies. A total
of 200 human sera were screened for immunoglobulin G
(IgG) antibodies against LPS from E. coli 0128:B12, 0127:
B8, 0111:B4, 055:B5, and 026:B6; S. abortus equi; and S.
typhi by the method of Gaffin et al. (10). The endotoxins
were coupled to microdilution plates (Greiner, Nurtingen,
Federal Republic of Germany) at an endotoxin concentration
of 70 ,ug/ml (10 ,ug/ml of each LPS) in 100 ,ul per well. The
wells were blocked with 10 mg of bovine serum albumin per
ml and 1 mg of gelatin per ml in pyrogen-free phosphate-
buffered saline. The sera to be tested were diluted 1:100 in
phosphate-buffered saline with 20% goat serum. Diluted sera
(100 ,u1 per well) were incubated in triplicate at 37°C for 1 h.
The bound IgG was detected by peroxidase-labeled goat
anti-human IgG (Medac, Hamburg, Federal Republic of
Germany) by using o-phenylenediamine (Sigma) as a sub-
strate. Concentrations of anti-LPS antibodies were deter-
mined by comparison to a standard of 100 p.g of anti-LPS
IgG per ml (a kind gift of S. L. Gaffin). The 10 sera with the
largest amounts of anti-LPS IgG showed cross-reactivity to
all LPS species used in screening for antibodies, when tested
separately.
Complement depletion. Freshly drawn human serum (2-ml
aliquots) was either incubated at 56°C for 30 min (to destroy
Cl, C2, CS, C8, C9, and factor B), treated with 1 ml of
packed baker's yeast at 37°C for 60 min (to deplete native
C3), or passed over a controlled pore glass column (Boehr-
inger GmbH, Mannheim, Federal Republic of Germany)
coupled with anti-human-C3c antibody (no. A062; Dako,
Hamburg, Federal Republic of Germany). The yeast was
killed by 56°C for 60 min and washed six times before
treatment of the serum. After treatment, the yeast was
removed by centrifugation and the serum was incubated for
a further 60 min at 37°C. Native control serum was stored on
ice until use (approximately 3 h). All samples were passed
through 0.22-p.m-pore-size cellulose acetate filters before
use in the monocyte assay, and aliquots were tested for total
hemolytic complement activity. Complete depletion of com-
plement was achieved by either method. Affinity column-
treated serum was also controlled for lack of C3 by rocket
immune electrophoresis.
RESULTS
Inactivation of LPS by human serum. Interaction of serum
from normal donors with LPS was studied first. Previous
experiments (27) had shown that freshly prepared mono-
cytes which are cultured in the presence of 10% serum
(human serum or FCS) will usually respond to minute
amounts of LPS (0.1 to 100 pg of LPS S. typhi per ml) by a
measurable release of IL-1. The threshold depended on the
sensitivity of the individual monocyte population, providing
that LPS was added at the start of the culture. Three parallel
series of experiments were performed to test the effect of
LPS-serum interaction upon monokine release. First, serial
log1o dilutions of LPS were incubated with serum-supple-
mented RPMI 1640 for 24 h at 37°C. Following this incuba-
tion period, the cell culture was initiated by the addition of
monocytes. Second, serum-supplemented culture medium
was incubated for 24 h at 37°C and LPS was added along
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FIG. 1. Effect of LPS-serum interaction on IL-1 release by
human monocytes. Monocytes were stimulated for 24 h with LPS S.
typhi in the doses indicated on the abscissa. Induced IL-1, as
measured by thymocyte assay and expressed in international units,
is shown on the ordinate. *, RPMI 1640, serum, LPS, and mono-
cytes added at start of the culture; 0, Serum-supplemented RPMI
1640 incubated for 24 h at 37°C, with LPS added at start of culture;
0, LPS incubated with RPMI 1640 and human serum for 24 h at
370C.
with monocytes at the start of the culture. Finally, all media
and agents (RPMI 1640, sera, LPS, and monocytes) were
added together at the start of the culture. Results of a
representative experiment out of a series of three repetitive
experiments are shown in Fig. 1. Incubation of LPS with
serum clearly reduced or abrogated measurable IL-1 release
by monocytes with concentrations of LPS S. typhi of .0.1
ng/ml. As a further control, a parallel dilution series of LPS
was incubated with culture medium RPMI 1640 alone and
serum was added with the monocytes. IL-1 release was
comparable to that of both other controls, showing that
adsorption of LPS to the plastic was not responsible for the
observed effects (data not shown).
Testing more than 50 monocyte preparations and sera
from 20 different donors revealed that the threshold dose of
LPS required for minimal IL-1 induction was always raised
by a factor of 10 to 100 following incubation with serum.
Inactivation of LPS by incubation with serum could not be
demonstrated under the given conditions when LPS S. typhi
was used in doses .10 ng/ml. The fact that inactivation of
LPS could always be overcome by high LPS doses excluded
toxicity of the employed serum preparations as a possible
mechanism of inactivation. All species of LPS tested (five
strains of E. coli and two of Salmonella species) and a
synthetic lipid A component could be inactivated. Inactiva-
tion could also be achieved with five human cord sera and
five batches of FCS. Finally, we tested pooled rat sera and
found the inactivation capacity to be at least 10 times greater
than that of human sera (data not shown).
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200 A Time kinetics and temperature dependence. To determine
the kinetics of LPS inactivation, LPS was incubated for
100
\different periods of time at 37°C with RPMI 1640 containing
100_ \\s\ human serum. With LPS doses of up to 300 pg/ml, significant
50 _O6Q\ \ inactivation was achieved within 3 h. Complete inactivationi~b _ \took 7 h. The results of one of two repetitive experiments are
shown in Fig. 2A. In this experiment, 1 ng of LPS S. typhi
per ml could not be inactivated completely within 24 h.
E 10 Similar results were obtained for induction of TNF-(x (Fig.
2B) and IL-6 (Fig. 2C). In separate experiments, larger LPS
- 5 doses (10 to 1,000 ng/ml) were incubated with serum-con-
taining medium for up to 1 week. There was no measurable
Rr.(2x \ \11effect upon IL-1 release as compared to the controls. The
J \ inactivation of LPS was largely dependent on the tempera-
31 \ \ ture. Incubation for 24 h at 4°C had no or only marginal
effects for LPS doses that were completely inactivated at
37°C. On the other hand, the degree of inactivation achieved
at 37°C after 24 h could be neither reversed nor increased by
0 1 3 5 7 24 an additional 24 h of incubation at 4°C (data not shown).
Inactivation of LPS by the lipoprotein-rich serum fraction.
Since binding of LPS to lipoproteins is well documented, we
15 suspected that lipoproteins might also be involved in LPS
Bn inactivation in our system. Using ultracentrifugation, we
prepared a serum devoid of lipoproteins. This lipoprotein-
*\ free serum (density of >1.21 g/cm3), which contained the
10 \ remaining serum proteins, was tested for its ability to
prevent LPS from inducing IL-1 release by monocytes. As
8 seen in Fig. 3A, incubation of LPS with lipoprotein-free
serum had no significant influence on the induced IL-1
E 6 0, release compared with the control. When, however, lipopro-
o ) s \ tein-free serum was reconstituted with the lipoprotein-rich
c \ + \ fraction (density of <1.21 g/cm3) to the original serum levels
(by apolipoprotein), this mixture had regained the capacity
4 to inactivate LPS upon incubation (Fig. 3B). The results
U. \ \ ' >,shown in Fig. 3 are from one representative experiment of a
z 3 1 9 series of five comparable tests. The effect of lipoproteins on
LPS was dose dependent. When graded amounts of lipopro-
b-00Y teins were titrated into lipoprotein-free serum, the mixture
I I1I I I showed increasing capacity to inactivate LPS proportional
0 1 3 5 7 24 to the amount of lipoproteins present (Fig. 4, results from
one of two experiments). To corroborate our assumption
that we were dealing with the effects of lipoproteins and not
with any effect of proteins contaminating the lipoprotein-rich
300 _ C fraction, we also tested other ways of removing lipoproteins
from serum, namely, adsorption to kaolin and extraction by
100 a solvent system (diisopropylether-butanol). Both manipula-tions resulted in a lipoprotein-free serum, which was unable
50 \ \ /A\ 1 to inactivate LPS upon incubation (data not shown).
> \</ \~N>oNutritive lipids and LPS inactivation. Since the lipoprotein-UsrR rich fraction also contained free lipids, we tried to determine
_
\ /A ' \ \ the influence of diet on inactivation of LPS by serum. A meal
E 30o rich in fatty acids and cholesterol was given to four personsprior to blood donation. As expected, their sera proved to be
5
FIG. 2. Time kinetics of LPS inactivation by human serum. (A)
Different doses of LPS S. typhi were incubated at 370C with
1 _ < serum-supplemented RPMI 1640 for the periods of time indicated on
the abscissa. Then, monocytes were added and cultured for another
.i,..^.24 h, and supernatants were tested for IL-1 by thymocyte assay.Activity of IL-1 in these supernatants is depicted on the ordinate.
O 1 3 5 7 24 (B) The same supernatants as in panel A were tested for TNF-a. by
ELISA, and concentrations are given on the ordinate. (C) The same
supernatants as in panel A were tested for IL-6 by induction of
Time of LPS-ser um hybridoma (7TD1 cell) proliferation. IL-6 activity is shown on the
incubat1ion (hour-s) ordinate. LPS amount: -4, 1 ng/ml; O----O, 0.6 ng/ml; 0-0,0.3 ng/ml;O0----0, 0.1lngIml.
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FIG. 3. Effect of removal of lipoproteins from human serum. (A)
LPS S. typhi was titrated into RPMI 1640 supplemented with
lipoprotein-free serum prepared by ultracentrifugation. LPS was
either added at start of culture together with the monocytes (0) or
incubated with supplemented RPMI 1640 for 24 h at 37°C previous to
the start of the monocyte culture (0). All other conditions are as
described in the legend to Fig. 1. (B) Same conditions as in panel A
except that lipoprotein-free serum was reconstituted with lipopro-
tein-rich fraction.
visibly lipemic. These sera were compared in regard to their
ability to inactivate LPS with sera from three blood donors
who had fasted overnight previous to blood donation. Both
groups of sera inactivated LPS to comparable extents (Table
1). It may be noted that lipemic sera caused somewhat
enhanced absolute counts per minute in low-power dilutions
of the thymocyte assay, possibly because of scavenging of
prostaglandins. The titers and units of IL-1 were, however,
unaffected. To avoid any unexpected influence, we did not
use lipemic sera in other experiments.
Influence of naturally occurring antibodies against LPS.
Almost all human sera contain measurable amounts of
anti-LPS antibodies. We investigated whether the naturally
occurring antibodies against LPS would interfere with the
capacity of LPS to induce IL-1 release. Sera from normal
donors with high (>60 ,ug/ml) and low (<5 ,ug/ml) concen-
trations of anti-LPS IgG determined by ELISA were spiked
with the LPS species used to screen for antibodies. The sera
were incubated with LPS for 1 h at 4°C to avoid LPS
inactivation by lipoproteins and used in monokine produc-
tion. Comparison of sera with high and low anti-LPS con-
centrations showed no significant differences in IL-1 induc-
25
lipoprotein-rich fraction
in % of physiological con-
centrat;ion
FIG. 4. Titration of lipoproteins into lipoprotein-free serum. LPS
S. typhi was incubated for 24 h at 37°C with RPMI 1640 containing
a fixed amount of lipoprotein-free serum but different amounts of
lipoprotein-rich fraction. Following incubation, monocytes were
added and cultured for another 24 h. Final concentrations of LPS
were 0.1 ng/ml (0) and 1 ng/ml (0). Final concentrations of
lipoproteins are indicated on the abscissa, expressed as a percentage
of the original concentration of lipoprotein in serum.
tion (Table 2). Binding of naturally occurring antibodies
against LPS did not, therefore, influence IL-1 release in our
system. LPS inactivation by serum was also not due to
naturally occurring anti-LPS antibodies.
Influence of complement. LPS is known to activate the
bypass mechanism of complement activation. Monocytes
possess receptors for and are also possibly activated by
complement. Therefore, it was important to evaluate
whether complement depletion or activation might have any
influence on LPS inactivation observed in our system. We
approached this question by using C3-depleted serum and
serum treated at 56°C or yeast. Comparison of complement-
active serum with C3-depleted or yeast-treated serum re-
TABLE 1. Comparison of visibly lipemic human sera with sera
from fasted blood donors
IL-1 (IU/ml) (mean SD)
LPS S. typhi LPS incubated with serum LPS added at start of culture(ng/mI)a
Lipemic Nonlipemic Lipemic Nonlipemic
(n = 4) (n = 3) (n = 4) (n = 3)
10 101.0 ± 31.1 124.0 + 49.2 110.0 ± 24.5 99.3 + 29.1
1 36.3 + 7.7 36.3 + 10.1 110.5 ± 25.4 98.0 + 31.2
0.1 0 0 75.5 ± 8.1 70.3 + 34.8
a With no LPS, result was 0 for all columns.
I
1-
0 2.5 10
VOL. 57, 1989 2241
2242 FLEGEL ET AL.
TABLE 2. Comparison of IL-1 release induced by different LPSs in presence of normal human sera with low or high
concentrations of anti-LPS IgG
SourceoofnLPScanti-LPSofGa n IL-1 (lU/ml) (mean ± SD)b induced by LPS (nglml):Source of LPS ConntLP of'a ti-LPSIgG~~~~~~~ 10 1 0.1
E. coli 055:B5 Low 6 317.0 ± 107.9 249.0 ± 69.3 136.5 ± 44.3
High 6 273.0 ± 77.8 204.7 ± 26.2 144.0 ± 56.5
S. abortus equi Low 6 138.4 ± 25.7 158.4 ± 57.9 57.4 ± 39.7
High 6 138.2 ± 60.6 163.6 ± 61.0 54.6 ± 51.1
S. typhi Low 10 97.2 ± 47.7 121.4 ± 46.1 42.7 ± 12.9
High 10 87.5 + 28.0 113.0 ± 27.5 30.9 ± 16.8
E. coli 0127:B8 Low 10 239.6 ± 62.1 145.9 ± 33.2 36.5 ± 34.3
High 10 287.6 ± 67.0 203.3 ± 68.9 35.6 ± 25.4
E. coli 0128:B12 Low 10 130.0 ± 46.9 56.3 ± 39.3 28.4 ± 5.3
High 10 153.0 ± 55.5 71.5 ± 38.6 27.1 ± 4.8
E. coli 0111:B4 Low 10 292.3 ± 157.6 169.0 ± 117.8 0
High 6 313.0 ± 108.4 186.5 ± 49.1 0
E. coli 026:B6 Low 10 116.7 ± 39.1 10.5 ± 11.5 0
High 10 97.0 ± 30.9 8.0 ± 10.0 0
a Determined by ELISA.
b With no LPS, IL-1 induced was 0 IU/ml for all LPSs and all concentrations of IgG.
vealed that all three sera were equally supportive for mono-
cyte activation by low doses of LPS when LPS was added at
the start of the culture (Table 3). They were also comparable
in their capacity to inactivate LPS upon incubation. Heat
treatment (56°C, 30 min) of serum showed some influence on
the dose of LPS required for IL-1 induction. When 0.1 ng of
LPS S. typhi per ml was added at the start of the culture, this
dose was no longer sufficient to activate monocytes with this
serum. However, heat-treated serum still inactivated LPS
upon incubation (Table 3). Maximum stimulation by a high
dose of LPS (-1 V.g/ml; data not shown) was not affected at
all, excluding toxicity of heat-treated serum. All sera men-
tioned in Table 3 were prepared and tested twice. Repre-
sentative results are shown. Time kinetics experiments were
also performed with heat-treated serum. These experiments
revealed a slope parallel to that for native serum (data not
shown). The results indicate that the complement system, at
least starting from C3, is not involved in the LPS inactivation
described in this report. This is in agreement with our finding
that the capacity to inactivate LPS resides exclusively in the
lipoprotein-rich fraction.
DISCUSSION
Inflammatory cytokines such as TNF-ot and IL-1 appear to
mediate much of the LPS toxicity in vivo, as already pointed
out in the introduction. These cytokines are synthesized and
TABLE 3. Effect of complement depletion of sera upon
LPS inactivation
IL-1 (IU/ml) induced by LPS
Human serum Added at start Incubated with serum
Humanserum ~~(nglml) (nglml)
0.1 1 10 0.1 1 10
Nativea 78 130 103 0 0 103
Yeast treated' 73 NDb 98 0 ND 116
56'C treateda 0 ND 96 0 ND 33
C3 depleted" 95 190 210 0 0 200
a Results obtained in the same experiment by using identical monocyte
preparations.
b ND, Not determined.
' Results obtained by using a different monocyte preparation.
released by susceptible cells upon contact with LPS. It is
also known that serum components can interact with LPS
and reduce its toxicity in vivo. Earlier, we reported that LPS
S. typhi could be inactivated by incubation with serum from
healthy donors, such that the LPS could no longer activate
human monocytes to secrete IL-1 (27). The aim of this study
was to give a detailed analysis of the impact of the interac-
tion between LPS and serum on mediator secretion by
monocytes in vitro.
Our findings comprise three points. (i) We found that
under the conditions used, human serum could prevent the
activation of human monocytes by all different species of
LPS tested, including a synthetic lipid A, and that all three
monokines tested (TNF-ax, IL-1, and IL-6) were affected.
We therefore favor the view that inactivation described in
this system is not specific for the type of LPS and impairs
recognition of LPS by monocytes rather than merely modi-
fying the effect of LPS.
(ii) We found that the complement system and naturally
occurring antibodies against LPS are not involved in the
inactivation process described in this report. C3-depleted
serum and yeast-treated serum both behaved in a way
indistinguishable from that of native serum in our assay. This
demonstrates that under the conditions used, LPS activation
of monocytes, as well as serum inactivation of LPS, were
both independent of the complement system, at least starting
from C3, although complement may participate in separate
pathogenic mechanisms of LPS in vivo. Our results are in
agreement with those in a recent publication questioning
whether complement could activate monocytes at all (3).
Naturally occurring antibodies which are present in most
human sera are also not involved in the inactivation process
described, since high- and low-titer antisera, as well as FCS
(which contains no antibodies), had LPS-inactivating capac-
ities comparable to that of adult human serum. These results
do not exclude the possibility that antibodies may have
beneficial effects in vivo by affecting the clearance of LPS or
whole microorganisms (22). Nevertheless, the inability of
naturally occurring anti-LPS antibodies to prevent LPS
activation of monocytes may contribute to our understand-
ing of why the efficiency of therapy with anti-LPS plasma
remains controversial.
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Finally, we clearly show that the capacity of normal
human serum to inactivate LPS in regard to monokine
induction in vitro resides in the lipoproteins. Lipoproteins
are the sole fraction in normal human serum to have this
capacity, since lipoprotein-free serum did not show any LPS
inactivation at all in our system. This does not exclude the
possibility that the presence of nonlipoprotein serum com-
ponents may be necessary or beneficial for the LPS-inacti-
vating function of lipoproteins. Furthermore, components of
lipoprotein-free serum have been shown to inactivate LPS in
in vitro assays other than monocyte activation and to detox-
ify LPS in vivo (1, 2, 15, 35). The results obtained by
different investigators vary considerably, probably depend-
ing on the type of LPS, assay system, or in vivo model used
(see below). We therefore feel that data from other systems
may not be directly transferable to the human model. With
the data presented in this paper, we could link LPS-lipopro-
tein interaction to the inhibition of monocyte activation in a
human in vitro model. On the basis of our findings, we
speculate that LPS-lipoprotein interaction may well partici-
pate in reducing LPS toxicity in humans by suppressing
monokine release.
In the present report, we confined ourselves to the inves-
tigation of serum from healthy individuals to exclude possi-
ble interference from acute-phase proteins, including an
LPS-binding protein (35) and a macrophage factor control-
ling LPS-lipoprotein binding (44). Such acute-phase pro-
teins, elicited as a response to previous LPS challenge, may
interfere with the lipoprotein-dependent LPS inactivation in
vitro and may constitute different LPS-inactivating princi-
ples in vivo. It is known that the basal level of individual
acute-phase proteins present in normal serum varies widely
between different species. These differences may well con-
tribute to the massive variation of results in models from
different species.
The LPS-inactivating capacity of serum was resistant to
56°C and was optimal at 37°C; this is in agreement with
results of in vivo studies (41). The kinetics of the inactivation
were relatively slow. Together with the fact that the pres-
ence of serum is often viewed as a prerequisite for optimal
culture conditions (6), this may be the reason why LPS
inactivation has long gone undetected in systems using
monocytes/macrophages. At first glance, the amount of LPS
which can be inactivated by normal human serum (about 10
ng/ml) may also not seem very impressive. It may, however,
be significant, since monocytes can respond to picogram
concentrations of LPS (27). In relation to the extraordinary
sensitivity of monocytes to LPS, the inactivating capacity of
serum amounts to between 100- and 1,000-fold.
The amotints of LPS inactivated by serum as described
here are in contrast to the vast am,ounts of LPS which can be
bound by lipoproteins (39, 40). The mere binding of LPS to
lipoproteins can therefore not be equated with inactivation
of LPS. Hence, LPS inactivation as described in this report
may represent a distinct biological function of the lipopro-
teins. Our findings are in agreement with observations from
the literature which show that lipoprotein-complexed LPS
retained much of its biological activity (21, 25) or its toxicity
in animals (24, 38). The amounts of LPS used in these
experiments clearly exceeded the amounts which can be
inactivated as judged from our findings.
Using lipoprotein subfractioris, we observed that HDL
possess a rather small LPS-inactivating capacity compared
with that of the low-density lipoproteins (LDL) (W. A.
Flegel, manuscript in preparation). This observation is in
contrast to results of binding studies (39) showing that HDL
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FIG. 5. Proposed feedback mechanism for LPS detoxification by
lipoproteins in acute-phase reaction. Massive release of monokines
causes tissue damage and shock. Monokines also activate hepato-
cytes, leading to the acute-phase reaction, which includes changes
in serum levels of lipoproteins and changes in the ratio of lipoprotein
classes. These changes lead to an enhanced inactivation of LPSs.
Other acute-phase proteins which may constitute different ways of
endotoxin detoxification are not included in the figure (see text).
can bind more LPS than LDL can. Extrapolating our obser-
vations, we conclude that mere changes in the ratio of
lipoprotein classes may considerably alter the LPS-inacti-
vating capacity of total lipoproteins. A relative increase in
LDL and decrease in HDL should increase the LPS-inacti-
vating capacity of serum. Changes of composition and levels
of serum lipoproteins during the acute-phase response show-
ing the predicted pattern have recently been described (5, 11,
14, 16).
We believe that lipoproteins are likely to play a role in
handling and controlling the everyday influx of LPS from the
gut or minor infections. We speculate that lipoproteins
constitute a kind of buffer system for LPS, sheltering the
organism from being massively activated by minor amounts
of LPS, but low enough in their inactivating capacity to
allow for sensible activation of the immune system in case of
increased influx of LPS. In response to endotoxemia, the
inactivation capacity of serum could then be up-regulated by
a change of composition or concentration of serum lipopro-
teins in addition to the generation of other detoxifying
principles as mentioned above. Our view of a possible
regulation circuit contributing in part to the inactivation of
LPS is depicted schematically in Fig. 5.
In conclusion, we showed that lipoproteins contained in
normal human sera can interact with LPS to prevent LPS
from activating human monocytes in vitro. Lipoproteins are
the sole serum fraction of healthy individuals which has this
capacity. The LPS-inactivating capacity of lipoproteins is
clearly lower than their capacity to bind LPS. However, in
view of the exquisite sensitivity of monocytes to LPS, we
favor the concept that lipoproteins constitute a system to
control the effects of low doses of LPS on monocyte
activation in vivo. A shift of serum lipoprotein levels and
composition during the acute phase of an infection might
then contribute to an increased detoxification rate of LPS.
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